Organovo Holdings, Inc. (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, has recently begun commercial contracting for its second tissue service, the ExViveTM Human Kidney. This kidney proximal tubule model is a natural expansion of the Company’s preclinical product and service portfolio, allowing customers to study the effects of drug exposure on a key portion of the human kidney relevant to drug discovery and development. Organovo has already signed multiple commercial orders and is collaborating on toxicology panels and transporter studies, including with two global, top 25 pharmaceutical companies, as part of an early access program.
“The powerful data Organovo is releasing on the ExVive Kidney Tissue demonstrates significant potential value for our pharmaceutical customers,” said Keith Murphy, chairman and CEO of Organovo. “The compelling symphony of transporter function and the demonstration of a response to a known toxicant boost our excitement as we bring to market an advanced way to investigate preclinical kidney toxicity of new drug candidates.” The ExVive Human Kidney and Liver products are unique in the industry in the ability to replicate complex cell-cell interactions and key elements of native tissue architecture.